Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05980507 Withdrawn - Clinical trials for Relapsed/Refractory Multiple Myeloma

An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma

Start date: October 9, 2023
Phase: Phase 1
Study type: Interventional

An open label, single-arm clinical study evaluating the safety and efficacy of ICI201 infusion in relapsed/refractory multiple myeloma

NCT ID: NCT05918250 Withdrawn - Clinical trials for Relapsed or Refractory Multiple Myeloma

mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Start date: August 15, 2023
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.

NCT ID: NCT05647512 Withdrawn - Clinical trials for Relapsed or Refractory Multiple Myeloma

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Start date: January 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II Study of LM-305 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

NCT ID: NCT05513612 Withdrawn - Clinical trials for Acute Myeloid Leukemia (AML)

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Start date: August 1, 2020
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with hematopoietic and lymphoid malignancies.

NCT ID: NCT05493618 Withdrawn - Clinical trials for Multiple Myeloma, Refractory

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

Start date: December 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, New Jersey (NJ) (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma.

NCT ID: NCT05461209 Withdrawn - Clinical trials for Relapsed/ Refractory Multiple Myeloma

A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma

MonumenTAL-5
Start date: October 20, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of talquetamab versus belantamab mafodotin in terms of overall response rate (ORR) or progression-free survival (PFS).

NCT ID: NCT05408026 Withdrawn - Clinical trials for Relapsed or Refractory Multiple Myeloma

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Start date: October 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This phase II clinical trial design with a safety run-in period will be used to assess the rate of VGPR or better for the combination PVD-Dara in the treatment of RRMM.

NCT ID: NCT05362331 Withdrawn - Lymphoma Clinical Trials

Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The complex logistics and unique toxicities of chimeric antigen receptor T-cell (CAR-T) therapy require intensive patient education and careful monitoring. The Companion for CAR-T (CC) web app may be able to assist with patient education and preparation, communication between patients and their multidisciplinary teams, and home-based toxicity monitoring.

NCT ID: NCT05321862 Withdrawn - Multiple Myeloma Clinical Trials

Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.

PENTI-MIDAS
Start date: March 14, 2023
Phase: Phase 2
Study type: Interventional

The aim of our study is to confirm the relevance of PET using [68Ga]Ga-PentixaFor ligand, in comparison with FDG, for initial staging and detection of minimal residual disease in multiple myeloma patients eligible for autologous stem cell transplantation less than 66 years. The prognostic value of positive CXCR4 expression will also be assessed and [68Ga]Ga-PentixaFor/FDG discordances explored.

NCT ID: NCT05183139 Withdrawn - Multiple Myeloma Clinical Trials

A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma

US MM-7
Start date: June 30, 2022
Phase: Phase 4
Study type: Interventional

The main aim is to show that long-term use of ixazomib can improve symptoms of multiple myeloma and provide an effective long-term alternative treatment. Participants will take ixazomib orally (by mouth) with pomalidomide and dexamethasone or lenalidomide and dexamethasone in 28-day treatment cycles. Participants will be treated for a maximum of 39 cycles but may continue to receive ixazomib beyond 39 cycles if they are benefiting from it. A follow-up study visit will occur 30 days after the last dose of ixazomib. Participants will be monitored for up to 3 years.